When cancer patients encountered COVID-19: clinical characteristics and outcome in China
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.19965 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Guojing Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sc…. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, SARS-CoV-2. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Cancer patients were more likely to be affected by the coronavirus disease 2019 (COVID-19) pandemic. Therefore, we analyzed the clinical characteristics and outcomes in cancer patients who were infected with COVID-19 to determine if they were more vulnerable to COVID-19 than non-cancer patients. Methodology: This retrospective study involved 150 cancer patients and 300 non-cancer patients with a laboratory-confirmed diagnosis of COVID-19 at the Cancer Hospital of the Chinese Academy of Medical Sciences, at the end of 2022. Multivariable analysis was carried out on the factors associated with COVID-19 severity in cancer patients.
Results
Compared to the non-cancer group, the cancer group saw a notably higher number of hospitalizations and fatalities. Multivariate analysis showed that COVID-19 severity was correlated with male gender (OR: 5.60, 95% CI, 1.89-16.57), and recovery duration was longer than 10 days (OR: 3.19, 95% CI, 1.09-9.32) in the cancer group. However, the severity of COVID-19 was not made worse by the administration of systemic anticancer treatments prior to the outbreak.
Conclusions
During the COVID-19 Omicron epidemic, there seemed to be some association between various antitumor therapies, treatment intervals, and COVID-19 severity. The findings of this study can potentially help allay cancer patients` fears regarding COVID-19 infection and enable them to continue with crucial therapeutic processes for the treatment of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zitieren
APA
Wang, G., Dong, X., Huang, S., Xu, X., Wu, X., Yu, X., Gao, Q., Guo, K., Zhang, W., Wei, B., & Cui, W. (2024). When cancer patients encountered COVID-19: clinical characteristics and outcome in China. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19965
Vancouver
Wang G, Dong X, Huang S, Xu X, Wu X, Yu X, et al. When cancer patients encountered COVID-19: clinical characteristics and outcome in China. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19965
BibTeX
@article{Wang2024,
author = {Wang, Guojing and Dong, Xin and Huang, Shengkai and Xu, Xiaotian and Wu, Xi and Yu, Xueting and Gao, Quanquan and Guo, Kai and Zhang, Wenfeng and Wei, Baojun and Cui, Wei},
title = {When cancer patients encountered COVID-19: clinical characteristics and outcome in China},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.19965}
}
EUVIMED